SBIR/STTR Research Award

STTR Phase I:Steroid-eluting thread for the treatment of rhinitis

Award identifier 347017f60fb51ef2c267e9c0f06295c990bd9af85c6f42e39d4a9dc694d58168Awarding agency National Science Foundation

Award amount

$255,045

Program and phase

STTR · Phase I

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
SIMPLYBREATHE L.L.C.
Proposal award date
2023-09-15
Contract end date
2024-08-31
UEI
FXSHAPWAFFJ6
Solicitation number
NSF 22-551
Topic code
MD

Research abstract

The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients. A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists. The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit. The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies. _x000D_ _x000D_ This Small Business Technology Transfer Phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool. The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using Hot Melt Extrusion (HME). This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity. The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.